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Parkinsonism in frontotemporal dementia (FTD) was ﬁrst described in families with mutations in the
microtubule-associated protein tau (MAPT) and progranulin (PRGN) genes. Since then,mutations in several
other genes have been identiﬁed for FTDwith parkinsonism, including chromosome 9 open reading frame
72 (C9ORF72), chromatin modifying protein 2B (CHMP2B), valosin-containing protein (VCP), fused in sar-
coma (FUS) and transactive DNA-binding protein (TARDBP). The clinical presentation of patients with fa-
milial forms of FTD with parkinsonism is highly variable. The parkinsonism seen in FTD patients is usually
characterized by akinetic-rigid syndrome and is mostly associated with the behavioral variant of FTD
(bvFTD); however, some cases may present with classical Parkinson's disease. In other cases, atypical
parkinsonism resembling progressive supranuclear palsy (PSP) or corticobasal syndrome (CBS) has also
been described. Although rare, parkinsonism in FTD may coexist with motor neuron disease. Structural
neuroimaging, which is crucial for the diagnosis of FTD, shows characteristic patterns of brain atrophy
associatedwith speciﬁcmutations. Structural neuroimaging is nothelpful in distinguishing amongpatients
with parkinsonian features. Furthermore, dopaminergic imaging that shows nigrostriatal neuro-
degeneration in FTD with parkinsonism cannot discriminate parkinsonian syndromes that arise from
different mutations. Generally, parkinsonism in FTD is levodopa unresponsive, but there have been cases
where a temporary beneﬁt has been reported, so dopaminergic treatment is worth trying, especially, when
motor and non-motormanifestations can cause signiﬁcant problemswith daily functioning. In this review,
we present an update on the clinical and genetic correlations of FTD with parkinsonism.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).ayo Clinic Jacksonville, 4500
04 953 7229; fax: þ1 904 953
. Wszolek).
Ltd. This is an open access article u1. Introduction
In 1996, an international consensus conference was held in Ann
Arbor, MI, USA, to discuss the association of parkinsonism with
frontotemporal dementia (FTD), and the term Frontotemporal De-
mentia and Parkinsonism linked to chromosome 17 (FTDP-17) was
introduced [1]. At that time, 13 families were described as having
FTDP-17 with an autosomal dominant pattern of inheritance. Thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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behavioral changes, dementia, parkinsonism, amyotrophy, dysto-
nia, and supranuclear gaze palsy.
FTD is clinically characterized byearly behavioral changes and/or
language impairment, which is followed by cognitive decline and
dementia. Parkinsonism is usually present in the behavioral variant
of FTD (bvFTD), but it is rarely seen in primary progressive aphasia
(PPA),which is a language variant of FTD [2e4]. Parkinsonism in FTD
may present before, during, or after the development of behavioral
or language disturbances. The clinical manifestations of parkin-
sonism seen in FTD patients are varied. Parkinsonian syndrome in
FTD ranges from an apparent classical presentation of Parkinson's
disease (PD) to atypical parkinsonism that resembles progressive
supranuclear palsy (PSP) and corticobasal syndrome (CBS) [2].
Up to 40% of FTD patients have a positive family history, which
suggests a strong genetic component to these disorders. It is esti-
mated that autosomal dominant cases account for over 13% of the
total number of FTD cases [5,6]. Currently, the best understood
forms of autosomal dominant FTD associated with parkinsonism
are those linked to chromosome 17 and related to mutations in the
microtubule-associated protein tau (MAPT) and progranulin (PGRN)
genes [7e9]. Besides MAPT and PGRN, the chromosome 9 open
reading frame 72 (C9ORF72) gene, which was identiﬁed in 2011,
is known to be the major causative gene for familial FTD
that is also associated with parkinsonism [10,11]. Mutations in
four other genes: chromatin modifying protein 2B (CHMP2B),
valosin-containing protein (VCP), transactive DNA-binding protein
(TARDBP), and fused-in-sarcoma (FUS) are identiﬁed in a minority
of FTD cases accompanied by the parkinsonian phenotype [12e15].
In this review we describe the clinical features in familial FTD with
parkinsonism with known genetic defect.
2. Clinical genetics, general characteristic, and parkinsonian
features in familial FTD with parkinsonism
Molecular genetic studies in patients with FTD associated with
parkinsonism have identiﬁed mutations in several genes: MAPT,
PGRN, C9ORF72, CHMP2B, and VCP. Mutations found in common ALS
genes, TARDBP and FUS, may also contribute to FTD associated with
parkinsonism (Table 1). Parkinsonism seen in FTD patients carrying
different autosomal dominant gene mutations can have a diverse
clinical manifestation. In Table 2 we provide a summary ofTable 1
The proﬁle of genes associated with parkinsonism in FTD.
MAPT PGRN C9OR
Chromosomal localization 17q21.32 17q.21.31 9p21
Inheritance AD AD AD
Penetrance Almost 100% 90% by 70 years Prob
Anticipation 0 þ þþ
Estimated mutation frequency in FTD 0e50% 3e26% 14-4
Mean AAO (range) 49 years (25e76) 59 years (44e83) 55 y
Mean DD (range) 7 years (2e30) 7 years (1e14) 4.5 y
Most frequent initial Dx. bvFTD ± P bvFTD ± P FTD/
Clinical Dx. during the
disease course
Most
frequent Dx.
FTD
Parkinsonism
FTD
CBS
FTD
MND
Relatively
common Dx.
Pyramidal signs
PSP
Parkinsonism
Pyramidal signs
Park
Rare Dx. CBS
MDSa
MDSa
Hallucinations
CBS
Prominent neuropathology Tau TDP-43 TDP-
AAO ¼ age at onset; AD ¼ autosomal dominant; ALS ¼ amyotrophic lateral sclerosis
Dx.¼ diagnosis; FTD ¼ frontotemporal dementia; FUS¼ fused in sarcoma; IBMPFD¼ incl
P ¼ Parkinsonism; TDP-43 ¼ transactive DNA-binding protein; U ¼ ubiquitin; UKN ¼ un
a Includes upper and lower motor neuron deﬁcits.parkinsonian features and other motor and non-motor manifesta-
tions that could be present in patients with FTD.
2.1. FTDP-17 (MAPT)
Mutations in the MAPT account for up to approximately 50% of
FTD cases and the majority of FTDP-17 cases. Over 50 pathogenic
MAPT mutations have been described (www.molgen.ua.ac.be/
FTDMutations) [16]. The mode of inheritance is autosomal domi-
nant. The mean age at onset is 49 years, but this can range from 25
to 76 years. The mean disease duration is approximately 7 years,
but the disease duration could be longer; for example, tau p.R406W
mutation carriers can survive into the eighth decade of life
[12,17e19]. A positive family history is almost always present in
MAPT mutation carriers, and their penetrance is nearly 100% [20].
No gender predilection has been identiﬁed [21]. The clinical pre-
sentation of FTDP-17 (MAPT) is variable, but cardinal signs include
personality and behavioral changes, dementia, and parkinsonism.
At the onset of the disease, only one of these signs is typically
exhibited, but in advanced disease stages, all of the signs could be
present. Based on the type of MAPT mutation, the initial FTDP-17
phenotype can be divided into frontotemporal dementia-
predominant or parkinsonism-predominant [22]. However, the
most common clinical presentation of FTDP-17 (MAPT) is bvFTD.
FTDP-17 (MAPT) patients experience slowly progressive dementia
with gradual functional decline. Motor neuron deﬁcits such as
amyotrophy and fasciculation are rarely seen [23e25].
2.1.1. Parkinsonism in FTDP-17 (MAPT)
Parkinsonism can be the ﬁrst manifestation of FTDP-17 caused
by mutations in MAPT (FTDP-17 (MAPT)), and it can initially have a
good response to levodopa therapy. Because of this, some patients
could be misdiagnosed as having PD at the early stage of the dis-
ease. When parkinsonism is the ﬁrst symptom of FTDP-17, it is
usually caused by mutations in exon 10 of theMAPT gene (p.N279K,
p.delN296, p.S305S, p.N296N, and p.G303V) [17,25]. However in
some FTDP-17 (MAPT) mutations, parkinsonism occurs late in the
disease course (p.P301S and p.N296H), or is rare and minimal
(p.P301L, p.S305N and p.G272V). Parkinsonism seen in FTDP-17
(MAPT) patients includes severe limb bradykinesia, axial and limb
rigidity, and postural instability. These signs are often symmetric,
and there is usually no resting tremor. Postural or action tremorF72 CHMP2B VCP TARDBP FUS
.2 3p11.2 9p13.3 1p36.22 16p11.2
AD AD AD AD
ably high UKN Incomplete UKN UKN
UKN UKN UKN UKN
8% <1% <1% <1% <1%
ears (33e75) 58 years
(46e71)
55 years
(37e79)
54 years
(35e74)
43 years
(30e60)
ears (3e10) 10 years (5e21) 6 years (1e21) 3 years (1e6) 3 years (3e7)
ALS ALS, FTD IBMPFD ALS, bvFTD FTD, ALS
a
FTD
Dementia
FTD
MNDa
MNDa FTD
MNDa
insonism Parkinsonism Dementia FTD
Parkinsonism
Dementia
MNDa
Epilepsy
Language
impairment
Parkinsonism
Dementia Parkinsonism
43, U U TDP-43 TDP-43 FUS
; bvFTD ¼ behavioral variant frontotemporal dementia; DD ¼ disease duration;
usion body myopathy and Paget's disease of the bone and frontotemporal dementia;
known; 0 ¼ not present; (þ) ¼ present in some cases; (þþ) ¼ frequent.
Table 2
Summary of characteristics of parkinsonism and motor and non-motor manifestations seen in patients carrying autosomal dominant genes mutations for FTD associated with
parkinsonism.
MAPT PGRN C9ORF72 CHMP2B VCP TARDBP FUS
Parkinsonism
Bradykinesia þþþ þþþ þþ þ þþ þþ þþ
Rigidity þþþ þþþ þþ þþ þ þþ þ
Postural instability þþ þþ þ    
Resting tremor  ± ±  ± þ 
Gait impairment þ þ þ þ  
PSP phenotype
Supranuclear gaze palsy þþ þ þ þ   þ
Difﬁculty initiating saccades þþ þ þ þ   þ
CBS phenotype
Apraxia þ þþ þ þþ þþ  þ
Cortical sensory loss  þ þ    
Alien limb phenomenon  þ þ    þ
Other movement disorders
Tremor (except resting tremor) ±   þ   
Dyskinesia    þ þ  
Dystonia þ þ þ þ þ þ 
Myoclonus þ þ  þ þ  
Chorea       ±
Tics      þ 
RBD     ± þ 
Restless legs syndrome       
Asymmetry  þþ þ   þ 
Levodopa responsiveness
Might be temporarily
effective
Usually not
effective
Might be temporarily
effective
UKN Might be
effective
Effective UKN
CBS ¼ corticobasal syndrome; PSP ¼ progressive supranuclear palsy; RBD ¼ REM behavioral sleep disorder; UKN ¼ unknown; () ¼ not present/not assessed;
(±) ¼ infrequent; (þ) ¼ present in some cases; (þþ) ¼ moderate frequency; (þþþ) ¼ very frequent.
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are also described in association with MAPT mutations; these are
more likely associated with PSP syndrome than CBS. Parkinsonism
accompanied by oculomotor abnormalities is usually present in
patients with p.delN296, p.S305S, and p.N279K mutations; these
include slowed saccades, supranuclear gaze palsy resembling PSP
syndrome. Rarely, CBS with eyelid apraxia may be present in MAPT
mutations (p.P301S). Parkinsonism in FTDP-17 (MAPT) may also be
accompanied by bulbar symptoms, including dysarthria and
dysphagia, or corticospinal tract involvement, which may present
as hyperreﬂexia, clonus, extensor plantar responses, and dystonia
or myoclonus. Patients may occasionally respond to levodopa
therapy at the initial stage of their illness; however, that is rarely
sustained during the disease course [4,21,23,26]. There is no clear
association between cognitive decline and the presence, severity, or
onset of parkinsonism in FTDP-17 (MAPT). In mostMAPTmutations,Table 3
The MAPT mutations in FTDP-17 and their characteristic clinical phenotype.
Gene MAPT
Amino acid change N279K delN296 S305S N296N G30
Mutation type Point Deletion Silent Silent Poin
Genomic region Exon 10 Exon 10 Exon 10 Exon 10 Exon
AAO (years) 41e50 31e40 >50 >50 31e
DD (years) 6e10 5 6e10 6e10 5
Early parkinsonism þþþ þþþ þþþ þþþ þþþ
Late parkinsonism     
Rare parkinsonism     
Personality changes þþ  þþþ  
Dementia þþ þþþ þþþ  þ
Language difﬁculties þþ  þ þ þ
Supranuclear gaze palsy þþ þ þ þ þ
Apraxia þ   þ 
Pyramidal signs þþ  þ þ þ
Amyotrophy    þ 
AAO ¼ age at onset; DD ¼ disease duration; () ¼ not present/not assessed; (þ) ¼ rare;motor neuron disease is rarely present; however, p.K317M,
p.N296N, and p.P301L mutations could be associated with amyo-
trophy, fasciculation, and denervation. The most common MAPT
mutations associated with parkinsonian features and their clinical
presentations are summarized in Table 3.
2.2. FTDP-17 (PGRN)
Mutations in the PGRN account for up to approximately 26% of
FTD cases. More than 70 pathogenic PGRN mutations have been
described so far (www.molgen.ua.ac.be/FTDMutations). The mode
of inheritance is autosomal dominant. The mean age at onset is
around 59 years, almost a decade later than that of FTDP-17 (MAPT)
cases, but it can range from 44 to 83 years [3]. The disease duration
is variable and ranges from 1 to 14 years and is usually shorter on
average than that ofMAPTmutation carriers. PGRNmutations show3V K317M P301S N296H P301L S305N G272V
t Point Point Point Point Point Point
10 Exon 11 Exon 10 Exon 10 Exon 10 Exon 10 Exon 9
40 41e50 30 >50 41e50 31e40 41e50
6e10 6e10 5 6e10 5 6e10
þþþ     
 þþþ þþþ   
   þ þ þ
 þþþ þþ þþþ þþþ þþþ
þ þþþ  þþþ þþþ þþþ
þ þ þþ þ þ þ
þ þ þ  þ 
þ þ   þ 
 þ   þ 
þ   þ  
(þþ) ¼ present in some cases; (þþþ) ¼ frequent.
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years [27e30]. Awide spectrum of cognitive, behavioral, and motor
features in FTDP-17 is associated with PGRN mutations, but the
particular type of mutation does not predict the clinical syndrome
[27e29,31,32]. PGRN mutations are usually associated with bvFTD,
but unlike MAPT mutation carriers, an isolated language dysfunc-
tion and primary progressive aphasia syndrome (PPA) can be also
observed [3]. A careful language evaluation may help to predict
PGRN mutations in FTDP patients [33]. Measurement of serum
progranulin levels, which are extremely low in PGRN mutation
carriers, may help achieve a correct diagnosis in FTDP-17 inde-
pendently of the phenotypic presentation when genetic testing is
unavailable. It has been suggested that this approach could be used
as a cost-effective prediction of PGRN mutations among FTDP-17
patients [33,34].2.2.1. Parkinsonism in FTDP-17 (PGRN)
Mild parkinsonism characterized by akinetic-rigid syndrome
occurs relatively frequently (40e60%) in patients with PGRN mu-
tations, but this is usually late in the disease course and occurs after
the development of FTD phenotype [9]. In minority of the cases
carrying PGRN mutations (p.Leu271LeufsX10), parkinsonism has
been described as a predominant clinical manifestation [4,31].
Some FTDP-17 cases with PGRN mutations present both visual
hallucinations and parkinsonism, which is suggestive of Lewy body
disease [21,35]. Some cases may have atypical parkinsonian fea-
tures characterized by progressive asymmetric rigidity and apraxia,
which is reminiscent of CBS (p.V200GfsX18, p.A9D and
p.E498DfsX12) [36]. Asymmetric apraxia that is consistent with
parietal lobe dysfunction and is associated with parkinsonian signs
that present early in the disease course may help distinguish PGRN
mutation carriers from other FTD patients with parkinsonian syn-
dromes. PGRN mutations are suggested to be one of the most
common causes of familial CBS [29]. Parkinsonism seen in FTDP-17
(PGRN) cases may initially respond to levodopa; however, in most
cases, it is not levodopa-sensitive [37,38]. The speciﬁc PGRN mu-
tations in which parkinsonism are most likely to be observed are
summarized in Table 4.2.3. C9ORF72 expansion
The C9ORF72 expansion accounts for up to approximately 48% of
FTD cases. The C9ORF72 gene located on chromosome 9 encodes
the chromosome 9 open reading frame 72 protein. Abnormal ex-
pansions of a noncoding GGGGCC hexanucleotide repeat
(700e1600 repeats) cause a variable combination of clinical phe-
notypes. The C9ORF72 expansion length in speciﬁc brain regionsTable 4
The PGRN mutations in FTDP-17 and their characteristic clinical phenotype.
Gene PGRN
Amino acid change R493X T304LfsX58 C253X A9D
Mutation type Point Insertion Deletion Point
Genomic region Exon 12 Exon 9 Exon 8 Exon 2
AAO (years) 44e62 57 60 46e59
DD (years) 3e9 5 NA 4e7
Parkinsonism þþ þ þ þ
Personality changes þ þ þþ þ
Dementia þ þ þ þ
Language difﬁculties þþ þ  þ
Supranuclear gaze palsy    þþ
Apraxia þ þ  þþ
Pyramidal signs  þ  
Amyotrophy    þ
AAO ¼ age at onset; DD ¼ disease duration; NA ¼ not present/not assessed; () ¼ absefrom autopsy cases with FTD and ALS revealed an association with
age at onset in the frontal cortex and disease duration in the cer-
ebellum, but a similar association was not detected in blood [39]. It
is not yet known whether the C9ORF72 expansion length contrib-
utes to the different phenotypes associated with the disease thus
further studies are needed. The mode of inheritance is autosomal
dominant. Anticipation was observed in some families. The age at
onset and disease duration is highly variable. Themean age at onset
is around 55 years (range 33e75 years). The mean disease duration
is approximately 4.5 years, and typically ranges from 3 to 10 years
[40,41]. The clinical phenotype of C9ORF72 expansion carriers
mainly consists of bvFTD, ALS, or FTD with motor neuron disease.2.3.1. Parkinsonism in C9ORF72 expansion
Parkinsonism is reported in about one-third of patients with
C9ORF72 expansions [41,42]. Parkinsonism in FTD due to C9ORF72
repeat expansions is usually characterized by a relatively sym-
metric akinetic-rigid syndrome and gait disturbances. Postural and
action tremors can occasionally be observed, but resting tremor is
rarely seen [40,43]. Parkinsonism is usually associated with pre-
dominant bvFTD or FTD/ALS, but this was not described in patients
with pure ALS [44,45]. Parkinsonism in C9ORF72 FTD patients may
remain pure, without associated cognitive deﬁcits or dementia for
over 10 years, but this is rare [45,46]. Cases that present with CBS or
PSP syndromes have also been described [47]. Parkinsonian fea-
tures in patients with C9ORF72 expansion typically evolve within
the ﬁrst years of the disease course and can temporarily be levo-
dopa responsive, but most patients do not beneﬁt from anti-
parkinsonian treatment [40].2.4. FTD-3 (CHMP2B)
In 2005, the CHMP2B gene, located on chromosome 3p11.2, was
associated with FTD linked to chromosome 3 (FTD-3) in large
kindred from Denmark and one unrelated Belgian familial FTLD
patient [29]. The CHMP2B gene mutations are currently understood
to be a rare genetic cause of familial FTD; only four pathogenic
mutations have been described (www.molgen.ua.ac.be/
FTDMutations). The mode of inheritance is autosomal dominant.
Since the disease has a subtle onset and often slow progression, the
exact age at onset can be difﬁcult to determine. The mean age at
onset has been reported to be around 58 years, and the mean
disease duration is approximately 10 years with great variability
[48,49]. CHMP2B mutation carriers typically present with bvFTD at
an early stage of their disease, but patients can develop more global
loss of cognition [50]. Infrequently, bvFTD can be accompanied by
motor symptoms, including parkinsonian features, dystonia,T7A G401X E498DfsX12 L271LfsX10 V200GfsX18
Point Point Deletion Deletion Point
Exon 2 Exon 11 Exon 12 Exon 7 Intron 7
50 55e69 NA 66 62
NA NA NA 1e8 9
þ þ þ þþþ þ
þ þþ þ þþ þ
þ þ þ þ þ
 þ þ þ 
    
þ þ þþ þþ þþ
    
    
nt; (þ) ¼ rare; (þþ) ¼ present in some cases; (þþþ) ¼ frequent.
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stages of the disease [51].
2.4.1. Parkinsonism in FTD-3 (CHMP2B)
bvFTD in FTD-3 can be accompanied bymotor symptoms, which
include parkinsonian features, dystonia, pyramidal signs and
myoclonus, but this ﬁnding is infrequent or is found late in the
disease course [51]. Classical parkinsonism is seen in a minority of
patients carrying CHMP2Bmutations, and it is usually characterized
by asymmetrical akinetic-rigid syndrome [50,52]. Parkinsonism in
FTD-3 typically occurs a few years after the symptomatic disease
onset. Rarely, an atypical parkinsonian phenotype that is accom-
panied by supranuclear gaze palsy or apraxia could be observed in
FTD-3. Responsiveness to levodopa therapy has not been reported.
2.5. VCP mutations
The VCP gene is located on chromosome 9p13.3 and encodes
valosin-containing protein. In 2004, a mutation in VCPwas found in
a rare autosomal dominant multisystem degenerative disorder,
inclusion body myopathy and Paget's disease of the bone and
frontotemporal dementia (IBMPFD) [53]. Over 15 potentially
pathogenic mutations in VCP have been described to date. The
phenotypic presentations within families with VCP mutations are
highly variable; about 35% of patients present with personality and
cognitive changes. VCP mutation phenotypes may also include
motor neuron degeneration in the form of familial ALS [54]. Several
affected individuals from families with IBMPFD and VCPmutations
have been reported to manifest with parkinsonism, especially in
the late disease stages [54e58].
2.5.1. Parkinsonism in VCP mutations
Several affected individuals from families with IBMPFD and VCP
mutations (p.R159C, p.R191Q, p.T262A, p.P137L, p.R191G, and
p.R159C) have been reported to manifest with akinetic-rigid parkin-
sonism that usually presents in the late disease stages [54,55,57,58].
Single cases with an p.R159Cmutation in the VCP have been reported
with typical PD features including resting tremor, REM sleep behav-
ioral disorder (RBD), and lasting levodopa responsiveness [53,54,59].
However, VCP is rarely associated with parkinsonism [53].
2.6. TARDBP mutations
In 2008, the TARDBP gene mutationwas identiﬁed as a causative
gene for ALS. The TARDBP gene, located on chromosome 1p36.22,
encodes a 43-kDa ubiquitously expressed nuclear DNA- and RNA-
binding protein (TDP-43) [60]. To date, more than 30 TARDBP mu-
tations have been reported, which explains approximately 4% of
familial ALS cases and a smaller proportion of FTD cases [61]. The
mode of inheritance is autosomal dominant. The most common
clinical phenotype associated with TARDBP mutations is ALS.
Several patients carrying TARDBP mutations have been reported to
develop parkinsonism [60e62].
2.6.1. Parkinsonism in TARDBP mutations
Several patients carrying TARDBPmutations have been reported
to develop parkinsonism in addition to the FTD phenotype [60e62].
An A382T mutation was described to be associated with a typical
PD phenotype or FTD with levodopa-responsive parkinsonism in
the absence of cognitive or motor neuron disturbances [60]. Other
mutation carriers (p.K263E, p.N267S, and p.A315E) presented with
a combination of parkinsonism and ALS and/or FTD. Parkinsonism
due to TARDBP mutations is characterized as a mixed type with
predominant akinetic-rigid syndrome and may be accompanied by
dystonia or tics. RBD was also reported in TARDBPmutation carrierswith parkinsonian features. Responsiveness to levodopa therapy is
typically good.
2.7. FUS mutations
In 2009, mutations in the FUS gene were originally described in
familial ALS. Mutations in the FUS account for up to 4% of familial
ALS cases [63]. The FUS gene, located on chromosome 16p11.2.,
encodes fused in sarcoma protein [64,65]. A number of speciﬁc
mutations in FUS have been suggested to cause FTD and essential
tremor [66,67]. In a cohort of 476 familial ALS and 41 sporadic ALS
cases, a family with the FUS p.R521C mutationwas identiﬁed in the
proband, who developed ALS with parkinsonism and dementia.
2.7.1. Parkinsonism in FUS mutations
A single case of a patient with a p.M254V mutation that was
associated with bvFTD and parkinsonian signs that developed
further in the disease course has been reported [15]. The parkin-
sonism in this case was characterized by rigidity; however, infor-
mation about other motor and non-motor manifestations and
responsiveness to levodopa was not provided. So far, very little is
known about FTD with parkinsonism due to FUS mutations.
Clinical characteristic of C9ORF72, CHMP2B, VCP, TARDBP, and
FUS genes mutations associated with parkinsonism in FTD are
summarized in Table 5.
3. Neuroimaging in FTD with parkinsonism
Structural neuroimaging (MRI) is essential to the evaluation of
patients with FTD, and characteristic patterns of brain atrophy are
associated with speciﬁc genetic mutations (Table 6). FTDP-17
(MAPT) typically shows symmetrical fronto-temporal lobe atro-
phy, with the most severe abnormalities observed in the temporal
lobes, whereas highly asymmetrical fronto-parieto-temporal atro-
phy is seen in FTDP-17 (PGRN) [68e70]. If symmetrical fronto-
temporal atrophy is associated with midbrain atrophy, usually
similar extrapyramidal features to those seen in PSP syndrome are
observed. The presence of early parietal lobe atrophy in patients
with PGRNmutationsmay help to distinguish such cases from other
patients with parkinsonian features in FTD. PGRN mutations are
also associated with faster rates of whole brain atrophy compared
to MAPT mutations [70]. It has been demonstrated that apart from
fronto-temporal pathology, atrophy in the occipital lobes and cer-
ebellum can help differentiate subjects with C9ORF72 mutations
from those with MAPT or PGRN mutations or sporadic disease
[10,11,42]. Structural neuroimaging studies of patients with
CHMP2B, VCP, TARDBP, and FUS mutations do not show speciﬁc
patterns of brain atrophy, but atrophy that is usually spread
throughout the frontal, temporal, and parietal lobes [12,71e74].
Structural neuroimaging cannot help distinguish between FTD
cases with and without parkinsonian features. Furthermore, in pa-
tients showing clear brain atrophy on MRI, little additional diag-
nostic beneﬁt is gained by doing single photon emission computed
tomography (SPECT) or positron emission tomography (PET) scans
because hypoperfusion and hypometabolism are usually present in
the same regions where MRI shows atrophy [75]. However, in pa-
tients with parkinsonism in FTD, perfusion SPECT with 99Technet-
ethylene cystine dimer (99Tc-ECD-SPECT) or 18F-ﬂuorodeoxyglucose
PET (FDG-PET)may conﬁrm the extrapyramidal systemdysfunction
by showing reduced cerebral blood ﬂow (99Tc-ECD-SPECT) and
hypometabolism (FDG-PET) in the basal ganglia [75e78].
Functional imaging with speciﬁc dopamine-related tracers (e.g.
99mTc-TRODAT-1, 123I-b-CIT, and 123I-FP-CIT for SPECT, and 18F-
DOPA, 11C-DOPA, and 11C-raclopride for PET) may assist in con-
ﬁrming the nigrostriatal neurodegeneration seen in various
Table 5
Speciﬁc mutations associated with parkinsonism in FTD and their characteristic clinical phenotype.
Gene C9ORF72 CHMP2B TARDBP VCP FUS
Amino acid change NA N143Sa A382T K263E N267S A315E R159C R191Q T262A P137L R191G M254Va R521C
Mutation type G4C2 hexanucleotide
repeat expansion
Point Point Point Point Point Point Point Point Point Point Point Point
Genomic region NA Exon 5 Exon 6 Exon 6 Exon 6 Exon 6 Exon 5 Exon 5 Exon 5 Exon 4 Exon 5 Exon 6 Exon 15
AAO (years) 33e75 71 53 35 69e74 57e63 50e73 37e63 51e56 38e50 42e45 52 NA
DD (years) 3e10 9 4 2 NA 4e6 1e5 1e7 4e15 10e21 9 NA NA
Parkinsonism þþ þ þþþ þ þ þ þ þ þ þ þþ þ þ
Personality changes þþþ þ þ þ þþ  þ þ þ þ  þ 
Dementia þ þ þ þ þ  þ þ þþ   þ þ
Language difﬁculties  þ   þ  þ þ þþ    
Supranuclear gaze palsy    þ         
Apraxia  þ           
Pyramidal signs þ þ    þþ þþþ þ  þþþ  þþ
Amyotrophy þþ  þ   þ þþþ þþþ þþ þþ þþþ  þþþ
AAO ¼ age at onset; DD ¼ disease duration; NA ¼ not present/not assessed; Sub ¼ substitution; () ¼ absent; (þ) ¼ rare; (þþ) ¼ present in some cases; (þþþ) ¼ frequent.
a Not proven to be pathogenic; only one mutations carrier has been identiﬁed for each mutation written in italics.
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may be used to discriminate between neurodegenerative parkin-
sonism and its mimics e.g. drug-induced parkinsonism [75]. In FTD
patients, where neuroleptics are widely used to assist with behavior
disorders, it is important to differentiate betweenparkinsonismwith
underlying neurodegenerative pathology and a drug-induced syn-
drome. Theuptakeof tracer is normal indrug-inducedparkinsonism,
and an abnormal image supports the diagnosis of dopaminergic
system neurodegeneration [79]. Unfortunately, neuroimaging of the
dopaminergic system has cannot differentiate between PD and
atypical parkinsonism well [75]. Furthermore, dopaminergic imag-
ing is not helpful in discrimination between different atypical
parkinsonian syndromes, including FTD with parkinsonism [80].
4. Pathologic ﬁndings in FTD with parkinsonism
Neuropathologically, FTD is deﬁned as Frontotemporal Lobar
Degeneration (FTLD), a proteinopathy characterized by the pres-
ence of abnormal protein inclusions in the cytoplasm or nuclei of
neuronal and glial cells. Parkinsonian features in FTD are most
likely associated with tau pathology (FTLD-tau). MAPT mutation
carriers with parkinsonism in FTD exhibit a combination of tau-
immunoreactive aggregates in neurons, astrocytes, and oligoden-
droglial cells that are localized in the cortex, basal ganglia, and theTable 6
Pattern of changes of neuroimaging in genetic forms of FTD associated with parkinsonis
MAPT PGRN C9ORF72
Asymmetry ± þþþ ±
Atrophy seen in structural neuroimaging studies (CT/MRI)
Frontal lobe þþþ þþ þþþ
Temporal lobe þþþ þþ þþ
Parietal lobe þ þþþ þ
Other regions  Basal ganglia Occipital lobe,
Thalamus Cerebell
Hypometabolism seen in 18FDG-PET
Frontal lobe þ þþ þþ
Temporal lobe þþ þþ þþ
Parietal lobe ± þþþ þ
Other regions Putamen, striatum  
Hypoperfusion seen in 99Tc-ECD-SPECT
Frontal lobe þþ þþ þþ
Temporal lobe þþ þ þþ
Parietal lobe þ þþ þ
Other regions  Hippocampus,
Cingulate cortex

CT ¼ computed tomography; MRI ¼ magnetic resonance imaging; 18FDG-PET ¼ 18F-ﬂ
ethylene cystine dimer single photon emission tomography; () ¼ not present; (±) ¼ in
frequent; NA ¼ not assessed.
a Limited information.subcortical white matter [65]. However, more than 50% of FTLD
patients present with tau-negative, TDP-43-positive ubiquitinated
neuronal and glial cytoplasmic inclusions (FTLD-TDP). TDP-43-
positive inclusions are the pathological hallmark in FTD with
parkinsonism caused by PGRN, C9ORF72, VCP and TARDBP muta-
tions. FUS mutation carriers have FUS-positive, and TDP-43-
negative inclusions and are thus referred to as FTLD-FUS. In
CHMP2Bmutation carriers the inclusion protein remains unknown;
they exhibit ubiquitin-positive but tau negative inclusions and TDP-
43-negative and FUS-negative cytoplasmic inclusions, which are
referred to as FTLD-ubiquitin proteasome system (FTLD-UPS),
previously known as FTLD-ubiquitin (FTLD-U) [81].
5. Differential diagnosis of parkinsonism in FTD
The main considerations in the differential diagnosis of
parkinsonism in FTD are other neurodegenerative diseases.
Parkinsonism in FTD is present in addition to behavioral and per-
sonality changes and usually occurs a few years after the cardinal
FTD symptoms are present.
Atypical parkinsonism with oculomotor disturbances and se-
vere postural instability causing frequent falls are characteristic for
PSP and can occur in the disease course of FTD with parkinsonism
caused by dominant gene mutations. The same is true for them (ﬁndings from structural and functional studies).
CHMP2Ba VCPa TARDBPa FUSa
þ þ þ þ
þ þ þþ þ
þ þ  þ
þ þ þ 
um
  Midbrain Caudate nucleus
þþ þþ þþ þ
þ þþ þ þ
þþ þ þ 
  Caudate nucleus 
NA þþ þþ NA
NA þþ þ NA
NA þ  NA
 Cerebellum Caudate nucleus,
Putamen

uorodeoxyglucose positron emission tomography; 99Tc-ECD-SPECT ¼ 99Technet-
frequent; (þ) ¼ present in some cases; (þþ) ¼ moderate frequency; (þþþ) ¼ very
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non-motor manifestations such as myoclonus and dystonia fol-
lowed by focal cortical deﬁcits, which are characteristic for CBS.
Conversely to sporadic disease, the PSP and CBS phenotypes
associated with FTD with parkinsonism usually develop after the
behavioral and personality changes that are characteristic for
bvFTD. MSA is mostly sporadic, progressive neurodegenerative
disease, but it is unlike FTD with parkinsonism where half of the
patients report positive family history. Furthermore, the parkin-
sonism found in MSA is associated with severe autonomic failure,
cerebellar ataxia, and corticospinal disorders, which are not usu-
ally seen in FTD. The main differences between FTD with parkin-
sonism and DLB are the rare visual hallucinations of FTD and the
dominant dementia and ﬂuctuations in cognitive status present in
DLB. Finally, the clinical presentations that are the hallmark of
typical PD are rarely seen in FTD patients with parkinsonism. The
presence of additional symptoms that are characteristic for bvFTD
and the lack of levodopa response in most cases should help
differentiate FTD with parkinsonism from classical PD.
6. Management of parkinsonism in FTD
Most patients with parkinsonism in FTD respond poorly to
levodopa (Table 2). There are no data on the use of dopamine ag-
onists in parkinsonism in FTD. Furthermore, dopaminergic agents
may trigger or exacerbate the psychiatric disturbances present in
FTD such as agitation, delusions, paranoia, and hallucinations.
Therefore, parkinsonism in FTD should be treated if it creates sig-
niﬁcant problems with daily functioning. Using anti-parkinsonian
agents requires empiric testing of tolerability and efﬁcacy [81]. In
the absence of pharmacological treatment, physical therapy can be
helpful to preserve mobility, to reduce risk of falls, and to extend
independence in activities of daily living [82].
7. Conclusion
In this review, we have summarized the current knowledge on
the clinical and genetic correlations of FTDwith parkinsonism. It has
become clear over the last two decades that there are multiple ge-
netic autosomal dominantmutations leading to the development of
FTD associated with parkinsonism. The most common causative
genes areMAPT, PGRN, and C9ORF72, but they are associated with a
wide range of phenotypes. Substantial evidence supports the
concept that FTD shares overlapping clinical features with other
neurodegenerative disorders. Parkinsonism in FTD may present as
classic PD (albeit rarely andusually early in the course of the illness);
and if so, it is characterized by an akinetic-rigid syndrome. In this
rare situation, it rather quickly evolves into the atypical parkin-
sonism with lack of responsiveness to levodopa. In most cases
parkinsonism even from its onset is of atypical nature resembling
phenotypes of PSPorCBS.Neuroimaging studies showcharacteristic
patterns of brain atrophy for different genemutations, but these are
not very helpful for the diagnosis of parkinsonism in FTD. A precise
diagnosis ismade throughagenetic testing.However, thereare still a
number of cases presenting with an FTD with parkinsonian pheno-
type, but without known genetic cause.
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